MedTrace Logo

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

NCT05371288 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2024-11-05

No results posted yet for this study

Summary

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium. Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status. They will also be asked to take blood samples.

Conditions

Interventions

DRUG

NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)

Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.

Sponsors & Collaborators

  • Hudson Valley Healing Arts Center

    collaborator UNKNOWN

  • University of California, Irvine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2025-09-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05371288 on ClinicalTrials.gov